Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Baricitinib for Treating Large Inflammatory Liver Adenomas in Women and Non-Resectable Cases in Men

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as inflammatory hepatocellular adenoma, which is a type of liver tumor. The study will explore the effects of a treatment using a medication called baricitinib, which is also known by its code names LY-3009104 and INCB-028050. Baricitinib is taken orally in the form of film-coated tablets, available in 2 mg and 4 mg doses. The purpose of the study is to determine if combining baricitinib with standard care, such as stopping estrogen-based contraception and losing weight if necessary, can significantly reduce the size of these liver tumors.

The study will involve participants taking baricitinib daily for a period of up to 26 weeks. Throughout the study, participants will undergo regular imaging tests, such as MRI scans, to monitor changes in the size of the tumors. The goal is to see if the treatment can lead to a decrease in tumor size by at least 30% in a significant number of patients. The study will also track any side effects or adverse events related to the treatment, including the occurrence of conditions like shingles, cancer, or major cardiovascular events.

Participants will be monitored for up to 24 months to assess the long-term effects of the treatment. This includes observing any changes in the tumors after stopping baricitinib and evaluating the need for liver surgery. The study aims to provide valuable insights into the effectiveness of baricitinib in treating inflammatory hepatocellular adenomas and improving patient outcomes.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, ensure that all eligibility criteria are met, including a confirmed diagnosis of inflammatory hepatocellular adenoma (HCA) through histology.

    Provide written informed consent for participation in the study.

  2. Step 2

    Initial assessment

    Undergo initial imaging to confirm the size and characteristics of the inflammatory HCA.

    Ensure that any estrogen-based contraception is discontinued if applicable, and consider weight loss if overweight.

  3. Step 3

    Treatment initiation

    Begin treatment with baricitinib, an oral medication. The dosage is 4 mg per day.

    Continue this treatment for a period of 6 months.

  4. Step 4

    Monitoring and follow-up

    Undergo MRI scans at 3 months and 6 months to assess the size of the HCA and any changes according to RECIST 1.1 criteria.

    Monitor for any adverse events related to the treatment, including potential side effects such as zona, cancer, or cardiovascular events.

  5. Step 5

    Treatment evaluation

    Evaluate the primary endpoint at 6 months to determine if there is a decrease in the target lesion size of at least 30%.

    Assess the overall radiological response, including partial and complete responses, stable disease, and progressive disease.

  6. Step 6

    Post-treatment follow-up

    After discontinuing baricitinib at 6 months, continue follow-up for up to 24 months.

    Monitor for any progression of the disease or changes in tumor size during this period.

Who can join the trial?

11 criteria

  • Women or men with a specific type of liver growth called **inflammatory HCA**. For women, at least one of these growths must be larger than 5 cm.
  • Must have had a past infection of the **Varicella zoster virus** (the virus that causes chickenpox) confirmed by a blood test or have been vaccinated against it more than 4 weeks before joining the study.
  • Must have medical insurance coverage.
  • Must provide written consent to participate in the study.
  • Must have a liver growth called **hepatocellular adenoma (HCA)** confirmed by a special review process.
  • Must have at least one HCA of the **inflammatory subtype** confirmed by special tests called **histology** and **immunohistochemistry**.
  • For women, must have at least one HCA larger than 5 cm confirmed by imaging tests.
  • The liver growth must have been diagnosed within the last 5 years.
  • Must not want to become pregnant while taking the study medication and for at least 4 weeks after the last dose.
  • Women who can have children must use a form of birth control that does not contain estrogen while taking the study medication and for at least 4 weeks after the last dose. If using oral birth control, it must have been used for at least one month before starting the treatment.
  • Men must use birth control when having sexual intercourse with a female partner while taking the study medication and for at least 4 weeks after the last dose.

Who cannot join the trial?

2 criteria

  • Women with an inflammatory HCA (Hepatocellular Adenoma, a type of liver tumor) that has been confirmed through a test called histology, and with at least one tumor larger than 5 cm.
  • Men with at least one inflammatory HCA confirmed by histology, regardless of the size, if the tumor cannot be removed as decided by a group of medical experts.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Baricitinib

    is an oral medication used in this trial. It is a JAK1/2 inhibitor, which means it works by blocking certain enzymes in the body that are involved in inflammation. In this study, it is being tested to see if it can help reduce the size of large inflammatory liver tumors known as hepatocellular adenomas.

  • Estrogen-based contraception discontinuation

    is part of the standard care in this trial. If patients were using estrogen-based contraceptives, they are asked to stop using them. This is because estrogen can sometimes contribute to the growth of certain types of liver tumors.

  • Weight loss

    is another component of the standard care in this trial. Patients who are overweight are encouraged to lose weight. This is because maintaining a healthy weight can help reduce the risk of liver problems and may contribute to the reduction of tumor size.

What is already known about the treatment

Baricitinib – This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating large inflammatory hepatocellular adenomas (HCA). It is primarily indicated for patients with inflammatory HCA, particularly women with tumors larger than 5 cm and men with non-resectable tumors. Baricitinib works by inhibiting the JAK1/2 enzymes, which play a role in the inflammatory process, thereby potentially reducing tumor size. It is classified as a JAK inhibitor and is being evaluated for its potential to complement standard care practices, such as discontinuing estrogen-based contraception and promoting weight loss.

Investigated diseases

Inflammatory Hepatocellular Adenoma (HCA) – Inflammatory Hepatocellular Adenoma is a type of benign liver tumor that is characterized by inflammation. It is more common in women and can be associated with the use of estrogen-based contraception. These adenomas can vary in size, and larger ones, particularly those over 5 cm, may pose a risk of complications. In men, these adenomas are considered non-resectable if surgery is not an option. The condition is identified through histological examination, which confirms the inflammatory nature of the adenoma. Over time, these adenomas may change in size, and monitoring is essential to assess any progression or regression.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-505278-13-00Protocol codeAPHP220916Estimated enrolment50 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.